Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS )

28.35 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. 
Via Benzinga
Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat
Apellis crashed after Syfovre safety issues continued to plague the stock. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Monday
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Via Benzinga
Apellis Pharmaceuticals Stock Slips Despite Q2 Sales Beat Thanks To Syfovre, Empaveli
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the  
Via Benzinga
Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Alphabet, Boeing, Union Pacific And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for  
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
APLS Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 40 stocks hit new 52-week lows. 
Via Benzinga
Apellis's Stock Under Pressure On Syfovre Safety Concerns: Analyst Slashes Price Target
Since Friday, Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS
From The Rosen Law Firm, P.A.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 46 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback